Stonepine Capital Management, LLC Uro Gen Pharma Ltd. Transaction History

Stonepine Capital Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$8.75 - $14.29 $2.21 Million - $3.62 Million	-253,027 Reduced 36.07%	448,508 $4.64 Million
Q1 2023 May 12, 2023	SELL	$7.99 - $11.02 $4.82 Million - $6.65 Million	-603,412 Reduced 46.24%	701,535 $6.48 Million
Q4 2022 Feb 14, 2023	BUY	$7.55 - $11.9 $1.36 Million - $2.15 Million	180,727 Added 16.08%	1,304,947 $11.6 Million
Q3 2022 Nov 10, 2022	BUY	$7.21 - $9.41 $94,955 - $123,929	13,170 Added 1.19%	1,124,220 $9.35 Million
Q2 2022 Aug 12, 2022	BUY	$5.12 - $8.74 $4.31 Million - $7.36 Million	842,217 Added 313.29%	1,111,050 $9.1 Million

Q1 2022 May 16, 2022	BUY	$5.92 - $9.73 $1.59 Million - $2.62 Million	268,833 New	268,833 $2.34 Million

113

24M

46.9K

44.3K

Ticker URGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 22,740,500
Market Cap $361M
Description
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...

Get notified when there are updates to the investment portfolio of Stonepine Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Stonepine Capital Management, LLC with notifications on news.